Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: "Dag Aarsland" Clear advanced filters

  • Cognitive impairment is common in patients with Parkinson disease and ranges in severity. This Primer reviews the epidemiology, pathophysiology, diagnosis and treatment of cognitive impairment in Parkinson disease and describes the effects on patient quality of life and the future outlook for the field.

    • Dag Aarsland
    • Lucia Batzu
    • Daniel Weintraub
    Reviews
    Nature Reviews Disease Primers
    Volume: 7, P: 1-21

  • Pain is a frequent complication that is experienced by elderly individuals, including those with dementia. Corbett et al. highlight how pain might represent an unmet need in patients with cognitive impairment and review the best available evidence for tools and interventions to assess and treat pain in the context of dementia.

    • Anne Corbett
    • Bettina Husebo
    • Clive Ballard
    Reviews
    Nature Reviews Neurology
    Volume: 8, P: 264-274

  • Most research into blood-based biomarkers for neurodegenerative disorders has so far focused on Alzheimer disease. In this Review, Aarsland and colleagues give an overview of the current status of blood-based biomarkers for the non-Alzheimer disease neurodegenerative disorders.

    • Nicholas J. Ashton
    • Abdul Hye
    • Dag Aarsland
    Reviews
    Nature Reviews Neurology
    Volume: 16, P: 265-284

  • The publication of a consensus definition of Parkinson disease (PD) psychosis in 2007 led to a rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. The authors review this literature and discuss the evolving view of PD psychosis, from distinct classes of symptoms to a continuum progressing over the course of PD.

    • Dominic H. ffytche
    • Byron Creese
    • Dag Aarsland
    Reviews
    Nature Reviews Neurology
    Volume: 13, P: 81-95

  • Dementia is commonly encountered in advanced stages of Parkinson disease (PD), but evidence is accumulating that cognitive decline can manifest much earlier in the disease course. Aarsland and colleagues review current knowledge regarding cognitive impairment in patients with PD, focusing on cerebrospinal fluid and imaging biomarkers as potential predictors of cognitive decline in this population.

    • Dag Aarsland
    • Byron Creese
    • Clive Ballard
    Reviews
    Nature Reviews Neurology
    Volume: 13, P: 217-231

  • Depression is a common symptom in patients with Parkinson disease (PD), and is found at higher rates in these individuals than in healthy populations or patients with other neurodegenerative disorders. Aarsland et al. discuss both the course of depression and the mechanisms that may contribute to the enhanced susceptibility to depression in patients with PD. Management strategies to control depression in these individuals are also highlighted.

    • Dag Aarsland
    • Sven Påhlhagen
    • Per Svenningsson
    Reviews
    Nature Reviews Neurology
    Volume: 8, P: 35-47

  • Despite a growing emphasis on biomarkers in research into Alzheimer disease (AD) and Parkinson disease (PD), there is little consensus as to which biomarkers are most effective. In this Review, Lleó and colleagues discuss cerebrospinal fluid (CSF) biomarkers for AD and PD, with a particular emphasis on applicability to clinical trials. Compared with AD, less is known about CSF biomarkers in PD, and the authors highlight several areas for further research.

    • Alberto Lleó
    • Enrica Cavedo
    • Brit Mollenhauer
    Reviews
    Nature Reviews Neurology
    Volume: 11, P: 41-55